
    
      OBJECTIVES:

        -  Determine the response rate in adult patients with relapsed or refractory acute myeloid
           leukemia or acute lymphoblastic leukemia treated with high-dose cytarabine followed by
           clofarabine.

      OUTLINE: This is an open-label phase II study. Patients are stratified according to diagnosis
      (acute myeloid leukemia vs acute lymphoblastic leukemia Phase II: Patients receive high-dose
      cytarabine followed by clofarabine (at the dose determined in phase I) on days 1-3.

      After completion of study treatment, patients are followed periodically for up to 5 years.

      PROJECTED ACCRUAL: A total of 39 patients were accrued for this study.
    
  